Taysha Gene Therapies Inc (TSHA)
3.09
-0.05
(-1.59%)
USD |
NASDAQ |
May 17, 16:00
3.08
-0.01
(-0.32%)
After-Hours: 20:00
Taysha Gene Therapies Shareholders Equity (Quarterly): 53.85M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 53.85M |
| December 31, 2023 | 74.94M |
| September 30, 2023 | -49.11M |
| June 30, 2023 | -37.11M |
| March 31, 2023 | -14.95M |
| December 31, 2022 | 0.949M |
| September 30, 2022 | 11.13M |
| June 30, 2022 | 32.71M |
| Date | Value |
|---|---|
| March 31, 2022 | 50.72M |
| December 31, 2021 | 95.38M |
| September 30, 2021 | 140.39M |
| June 30, 2021 | 186.50M |
| March 31, 2021 | 222.87M |
| December 31, 2020 | 251.30M |
| September 30, 2020 | 267.64M |
| June 30, 2020 | -8.772M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-49.11M
Minimum
Sep 2023
267.64M
Maximum
Sep 2020
79.90M
Average
52.29M
Median
Shareholders Equity (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | -36.30M |
| Lifecore Biomedical Inc | -1.842M |
| Relmada Therapeutics Inc | 72.05M |
| ACADIA Pharmaceuticals Inc | 464.04M |
| Cyclacel Pharmaceuticals Inc | 0.607M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 153.00M |
| Total Liabilities (Quarterly) | 99.15M |
| Debt to Equity Ratio | 0.7523 |
| Current Ratio | 3.380 |
| Net Debt Paydown Yield | -0.09% |